A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Results 1 to 2 of 2

Thread: Trial drug Gilteritinib question....for AML w/FLT3

  1. #1
    Newbie New User
    Join Date
    Oct 2018
    Posts
    1

    Trial drug Gilteritinib question....for AML w/FLT3

    Hello everyone! My name is Nachelle, I’m new to the forum. My fiancé Bobby was diagnosed in March this year with AML FLT3/ITD. He went into remission after the first cycle of chemo and recently we were told that his son is a half match for a bone marrow transplant. After hearing the severity of the bone marrow transplant, Bobby is understandably nervous about getting it. His medical team presented him with option to take a trial drug called Gilteritinib along with Rydapt or to take the trial after he completes the transplant. Has anyone here tried this trial drug before? Or does anyone have any advice on the bone marrow transplant itself? Any feedback that is offered will be greatly appreciated!

  2. #2
    Super Moderator Top User po18guy's Avatar
    Join Date
    Feb 2012
    Posts
    9,639
    Sorry to hear of his diagnosis, but good that he is in remission. Gilteritinib is so new, and with only 50 patients enrolled in the phase 1 trial, it is not very likely that recipients can be found. In any event, their tolerance of the drug and response rate to it apply only to them. The drug is aimed at relapsed or refractory AML, and this may not apply to your fiancé. Sadly, when one is in the the rare and aggressive cancer category, being a trailblazer can be a way of life.

    As to transplant, there is a dedicated transplant forum here. Several members have undergone donor transplants, and I have received a haploidentical transplant using my son's donor cells. Each transplant is 100% unique and no one else's experience will directly pertain to your fiancé.

    But, AML is very aggressive and outcomes are usually very poor. This would tend to lean in favor of a transplant. Engraftment of donor cells is virtually guaranteed in a haploidentical transplant. The downside is that transplant-related GvHD is potentially fatal and may need to be combated for life.

    https://www.cancerforums.net/forums/57-Transplant-Forum
    Last edited by po18guy; 10-09-2018 at 06:59 PM.
    05/08-07/08 Tumor appears behind left ear. Followed by serial medical incompetence on the parts of PCP, veteran oncologist and pathologist (misdiagnosis via non-diagnosis). Providential guidance to proper care at an NCI designated comprehensive cancer center.
    07/08 Age 56 DX 1) Peripheral T-Cell Lymphoma-Not Otherwise Specified. Stage IV-B, >50 ("innumerable") tumors, bone marrow involvement.
    08/08-12/08 Four cycles CHOEP14 + four cycles GND (Cyclofosfamide, Doxorubicin, Vincristine, Etoposide, Prednisone & Gemcitabine, Navelbine, Doxil)
    02/09 2) Relapse.
    03/09-06/13 Clinical trial of Romidepsin > long-term study. NED for 64 twenty-eight day cycles, dose tapered.
    07/13 3) Relapse, 4) Suspected Mutation.
    08/13-02/14 Romidepsin increased, stopped for lack of response. Watch & Wait.
    09/14 Relapse/Progression. Visible cervical nodes appear within 4 days of being checked clear.
    10/06/14 One cycle Belinostat. Discontinued to enter second clinical trial.
    10/25/14 Clinical trial of Alisertib/Failed - Progression.
    01/12/15 Belinostat resumed/Failed - Progression. 02/23/15
    02/24/15 Pralatrexate/Failed - Progression. 04/17/15
    04/15 Genomic profiling reveals mutation into PTCL-NOS + AngioImmunoblastic T-Cell Lymphoma. Stage IV-B a second time. Two dozen tumors + small intestine (Ileum) involvement.
    04/22/15 TREC (Bendamustine, Etoposide, Carboplatin). Full response in two cycles. PET/CT both clear. Third cycle followed.
    06/15-07/15 Transplant preparation (X-rays, spinal taps, BMB, blood test, MUGA scan, lung function, CMV screening, C-Diff testing etc. etc. etc.) Intrathecal Methotrexate during spinal tap.
    BMB reveals 5) 26% blast cells of 20q Deletion Myelodysplastic Syndrome MDS), a bone marrow cancer and precursor to Acute Myeloid Leukemia.
    07/11-12/15 Cyclofosfamide + Fludarabine conditioning regimen.
    07/16/15 Total Body Irradiation.
    07/17/15 Moderate intensity Haploidentical Allogeneic Stem Cell Transplant receiving my son's peripheral blood stem cells.
    07/21-22/15 Triple dose Cyclofosfamide + Mesna, followed by immunosuppressants Tacrolimus and Mycophenolate Mofetil.
    07/23-08/03/15 Marrow producing zero blood cells. Fever. Hospitalized two weeks.
    08/04/15 Engraftment occurs, and blood cells are measureable - released from hospital.
    08/13/15 Day 26 - Marrow is 100% donor cells. Platelets climbing steadily, red cells follow.
    09/21/15 Acute skin Graft versus Host Disease arrives.
    DEXA scan reveals Osteoporosis.
    09/26/-11/03/15 Prednisone to control skin GvHD.
    11/2015 Acute GvHD re-classified to Chronic Graft versus Host Disease.
    05/2016 Tacrolimus stopped. Prednisone from 30-90mg daily tried. Sirolimus begun.
    09/16/16 Three skin punch biopsies.
    11/04/16 GvHD clinical trial of Ofatumumab (Arzerra) + Prednisone + Methylprednisolone begun.
    12/16 Type II Diabetes, Hypertension - both treatment-related.
    05/17 Extracorporeal Photopheresis (ECP) begun in attempt to control chronic Graft-versus-Host-Disease (cGvHD.
    05/2017 Chronic anemia (low hematocrit). Chronic kidney disease.
    06/17 Trying various antibiotics in a search for tolerable prophylaxis.
    08/17 Bone marrow biopsy reveals the presence of 2% cells with 20q Deletion Myelodysplastic Syndrome, considered to be Minimum Residual Disease.
    12/17 Bone marrow biopsy reveals no abnormalities in the marrow - MDS eradicated. The steroid taper continues.
    01/18 Consented for Kadmon clinical trial of drug KD025, a ROCK2 inhibitor that is believed to help with chronic GvHD.
    03/18 Began 400mg daily of KD025, a rho-Associated Coiled-coil Kinase 2 Inhibitor (ROCK2).
    09/18 Due to refractory GvHD, treatment with Imbruvica (Ibrutinib) or clinical trial of Interleukin2 being considered.

    To date: 1 cancer, relapse, 2 cancers, then 3 cancers simultaneously, 18 chemotherapeutic drugs in 9 regimens (4 of them at least twice), 5 salvage regimens, 4 clinical trials, 4 post-transplant immuno-suppressant drugs, the equivalent of 1,000 years of background radiation from scanning from 45+ CT series scans and about 24 PET scans. Having had both lymphoid and myeloid malignancies lend a certain symmetry to the journey.

    Believing in the redemptive value of suffering makes all the difference.

 

Similar Threads

  1. Dual FLT3 Mutation
    By MarqueLarsen in forum Leukemia/Myelodysplastic Syndrome Forum
    Replies: 8
    Last Post: 07-22-2015, 08:25 PM
  2. Need information - Urgent (AML M2 FLT3 ITD)
    By tarak in forum Leukemia/Myelodysplastic Syndrome Forum
    Replies: 3
    Last Post: 06-08-2014, 09:32 PM
  3. First drug to target common target on all cancers goes to trial: AML up first!
    By hazellypoo in forum Leukemia/Myelodysplastic Syndrome Forum
    Replies: 0
    Last Post: 11-02-2013, 05:31 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •